Online citations, reference lists, and bibliographies.
← Back to Search

Single-agent Pegylated Liposomal Doxorubicin (PLD) In The Treatment Of Metastatic Breast Cancer: Results Of An Austrian Observational Trial

M. Fiegl, B. Mlineritsch, M. Hubalek, R. Bartsch, U. Pluschnig, G. Steger
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundIn advanced breast cancer, multiple sequential lines of treatments are frequently applied. Pegylated liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher lines of therapy. PLD has demonstrated response activity even after prior anthracycline exposure.Methods129 consecutive patients with advanced breast cancer, of whom the majority had been massively pretreated, received PLD as monotherapy within licensed approval, for which efficacy and toxicities were documented.ResultsIn a routine therapy setting, PLD was administered in a slightly reduced dose (median, 40 mg/m2 per cycle). Response rate (complete and partial remission) was 26%, and stable disease was observed in 19% of patients. Progression-free (PFS) and overall survival (OS) were 5.8 months and 14.2 months, respectively. There was no difference in terms of response and PFS, no matter if patients had already received anthracycline treatment. Interestingly, PFS proved similar regardless whether PLD was administered as palliative therapy in first, second or third line. Furthermore, PFS and OS were similar in patients with response or stable disease, underscoring the view that disease stabilization is associated with a profound clinical benefit. The most common side effects reported were palmar-plantar erythrodysesthesia (17%), exanthema (14%) and mucositis (12%).ConclusionsEfficacy and toxicity data in these "real life" patients permit the conclusion that PLD is a valuable option in the treatment of advanced breast cancer even in heavily pretreated patients.
This paper references
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1016/j.ejca.2008.01.028
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
R. von Moos (2008)
10.1038/sj.bjc.6603158
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S. Al-Batran (2006)
10.1002/j.1552-4604.1996.tb04152.x
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
Central European Cooperative Oncology Group (CECOG): Third consensus on medical treatment of metastatic breast cancer
S Beslija (2009)
Demissie K: Missing paternal demographics: A novel indicator for identifying high risk population of adverse pregnancy outcomes. BMC Pregnancy Childbirth 2004, 4:21. Pre-publication history The pre-publication history for this paper can be accessed here:
10.1159/000093005
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)
10.1007/S12254-009-0113-Y
Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei
Wan-ling Sun (2009)
10.1159/000080363
Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure
B. Mlineritsch (2004)
10.1038/sj.bjc.6605961
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
S. Al-Batran (2010)
10.1093/ANNONC/MDP261
Third consensus on medical treatment of metastatic breast cancer
D. Berthold (2006)
10.1186/1471-2407-10-2
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
J. Huober (2009)
10.1081/CNV-120014883
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
A. Perez (2002)
10.1200/JCO.2007.11.9776
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
R. Bartsch (2007)
Anichstrasse 35, Innsbruck, Austria. 2 Department of Internal Medicine III, Private Medical University of Salzburg, Müllner Hauptstrasse 48
10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
10.1186/1471-2407-9-367
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
R. Bartsch (2009)
10.1002/cncr.22263
Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia
M. Fiegl (2006)
10.1007/s10549-010-0860-9
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
E. Alba (2010)
10.1200/JCO.1997.15.10.3185
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
10.1016/J.EJCA.2005.12.011
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
10.1200/JCO.2004.08.157
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after firstline treatment failure
B Mlineritsch (2004)
J Clin Oncol
(2008)
10.1007/s10549-008-0132-0
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
R. Bartsch (2008)
Central European Cooperative Oncology Group (CECOG): Third consensus on medical treatment of metastatic breast cancer
C Wiltschke (2009)
10.1200/JCO.2008.26.15_SUPPL.19063
Twelve-year retrospective analysis of lung cancer--The TYROL Study: Daily routine in 1,424 patients (1995-2006)
M. Fiegl (2008)
10.1007/s00432-008-0372-8
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
F. J. F. Broeyer (2008)
10.1093/ANNONC/MDL477
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
D. Lorusso (2007)
10.1186/1471-2407-9-130
Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
J. Vardy (2008)
Toxic effects occurring during treatment of advanced breast cancer with PLD (described in at least 2 PLD-treated patients) Toxic effects
S Beslija (2011)
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (’hand-foot
D Lorusso (2007)
10.1007/s10549-010-0925-9
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer
C. G. Murphy (2010)
10.1007/S12254-008-0051-0
Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation
K. Prassl (2008)



This paper is referenced by
10.1016/j.actbio.2020.04.029
Bispecific Antibody (HER2 × mPEG) Enhances Anti-Cancer Effects by Precise Targeting and Accumulation of mPEGylated Liposomes.
I. Chen (2020)
10.1186/s12885-015-1433-4
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
K. Rau (2015)
10.4236/abcr.2020.92003
Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer
S. Khallaf (2020)
10.1016/j.ejca.2013.04.027
Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
C. Falandry (2013)
10.4103/2045-080X.174930
A comparison between liposomal and nonliposomal formulations of doxorubicin in the treatment of cancer: An updated review
Yik Hoe Ngan (2016)
10.1016/J.PHYSB.2017.12.036
Effects of doxorubicin on the structural and morphological characterization of solid lipid nanoparticles (SLN) using small angle neutron scattering (SANS) and small angle X-ray scattering (SAXS)
F. Yokaichiya (2017)
Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.
A. Pircher (2013)
10.2459/JCM.0000000000000382
Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies
C. Cadeddu (2016)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.1007/s40259-013-0070-1
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
K. Lyseng-Williamson (2013)
10.4103/2278-0513.149025
Adverse drug reaction profile of pegylated liposomal doxorubicin versus conventional doxorubicin: An observational study
Aloke Ghosh Dastidar (2015)
10.1016/j.nano.2020.102197
Biologicals to direct nanotherapeutics towards HER2-positive breast cancers.
G. Kumar (2020)
10.3747/co.19.1024
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.
J. Ayoub (2012)
10.1186/s12885-016-2385-z
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
K. Miller (2016)
10.1097/CAD.0000000000000037
Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
J. Rom (2014)
10.3390/biomedicines4030022
An Abraded Surface of Doxorubicin-Loaded Surfactant-Containing Drug Delivery Systems Effectively Reduces the Survival of Carcinoma Cells
C. Schmidt (2016)
10.1186/s43046-020-00034-4
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
S. Khallaf (2020)
10.24087/IAM.2018.2.1.386
Sustainability of Eribulin Treatment for Patients with Metastatic Breast Cancer: is the Cost of the Drug Related to the Benefit Produced (Effectiveness and Safety)? a Single Center Experience
Garipoli Claudia (2017)
10.1038/s41416-018-0235-2
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
P. Munster (2018)
10.1007/s00280-017-3279-8
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
A. Rocca (2017)
10.1111/bph.12202
Increasing doxorubicin activity against breast cancer cells using PPARγ‐ligands and by exploiting circadian rhythms
I. S. Arif (2013)
Semantic Scholar Logo Some data provided by SemanticScholar